Risk factors of treatment discontinuation due to uterine bleeding in adenomyosis patients treated with dienogest

Journal of Obstetrics and Gynaecology Research

Volumn 38, Issue 4, 2012, Pages 639-644

  Nagata, Chie ^a   Yanagida, Satoshi ^a   Okamoto, Aikou ^a   Morikawa, Asuka ^a   Sugimoto, Kohei ^a   Okamoto, Shigehisa ^b   Ochiai, Kazunori ^a   Tanaka, Tadao ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Okamoto Women's Clinic   (Japan)

Author keywords

Adenomyosis; Adverse effect; Dienogest; Endometriosis; Uterine bleeding

Indexed keywords

DIENOGEST; ESTRADIOL; HEMOGLOBIN;

ADENOMYOSIS; ADULT; AGE; ARTICLE; DISEASE COURSE; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD; RISK FACTOR; UTERUS BLEEDING;

ADULT; ENDOMETRIOSIS; FEMALE; HEMOGLOBINS; HUMANS; MIDDLE AGED; NANDROLONE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; UTERINE HEMORRHAGE;

EID: 84860878091     PISSN: 13418076     EISSN: 14470756     Source Type: Journal    
DOI: 10.1111/j.1447-0756.2011.01778.x     Document Type: Article

References (16)

1. Kennedy S, Bergqvist A, Chapron C et al. ESHRE guideline for the diagnosis and treatment of endometriosis. Hum Reprod 2005; 20: 2698-2704. (Pubitemid 41487622)
2. Giudice LC, Kao LC. Endometriosis. Lancet 2004; 364: 1789-1799. (Pubitemid 39488065)
3. Japan Society of Obstetrics and Gynecology. The General Rules for Clinical Management of Endometriosis, 2nd edn. Tokyo: Kanehara & Co., Ltd., 2010.
4. Oettel M, Bervoas-Martin S, Elger W et al. A 19-norprogestin without 17a-ethinyl group II: Dienogest from a pharmacokinetic point of view. Drugs Today 1995; 31: 499-516. (Pubitemid 26031141)
5. McCormack PL. Dienogest: A review of its use in the treatment of endometriosis. Drugs 2010; 70: 2073-2088.
6. Cosson M, Querleu D, Donnez J et al. Dienogest is as effective as triptorelin in the treatment of endometriosis after laparoscopic surgery: Results of a prospective, multicenter, randomized study. Fertil Steril 2002; 77: 684-692. (Pubitemid 34275344)
7. Harada T, Momoeda M, Taketani Y et al. Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis - a randomized, double-blind, multicenter, controlled trial. Fertil Steril 2009; 91: 675-681.
8. Strowitzki T, Marr J, Gerlinger C, Faustmann T, Seitz C. Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: A 24-week, randomized, multicentre, open-label trial. Hum Reprod 2010; 25: 633-641.
9. Momoeda M, Taketani Y, Terakawa N, Aso T, Tsutani K. Randomized double-blind, multicentre, parallel-group dose- response study of dienogest in patients with endometriosis. Jpn Pharmacol Ther 2007; 35: 769-783.
10. Irahara M, Harada T, Momoeda M, Tamaki Y. Hormonal and histological study on irregular genital bleeding in patients with endometriosis during treatment with dienogest, a novel progestational therapeutic agent. Progr Reprod Biol Med 2007; 6: 223-228. (Pubitemid 350066668)
11. Miyazaki T, Yoshimura Y. Endometriosis, Adenomyosis. Comprehensive Handbook of Women's Medicine 19. Taketani Y, (ed). Tokyo: Nakayama-Shoten Co., Ltd., 1999.
12. Yoshimura Y. How to use GnRH analogs. (in Japanese). Sanfujinka No Sekai 2001; 53: 719-728.
13. Schindler AE. Dienogest in long-term treatment of endometriosis. Int J Womens Health 2011; 3: 175-184.
14. Petraglia F, Hornung D, Seitz C et al. Reduced pelvic pain in women with endometriosis: Efficacy of long-term dienogest treatment. Arch Gynecol Obstet 2011 doi 10.1007/s00404-011- 1941-7.
15. Momoeda M, Harada T, Terakawa N et al. Long-term use of dienogest for the treatment of endometriosis. J Obstet Gynaecol Res 2009; 35: 1069-1076.
16. Kitawaki J, Kusuki I, Yamanaka K, Suganuma I. Maintenance therapy with dienogest following gonadotropin-releasing hormone agonist treatment for endometriosis-associated pelvic pain. Eur J Obstet Gynecol Reprod Biol 2011; 157: 212-216.